Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy.

All except two patients were in complete remission at the time of first vaccine, while three patients were still on therapy (revlimid I n i = 1, tafasitamab I n i = 1, chemotherapy I n i = 1). Keywords: COVID 19; vaccine; CAR-T cells; BNT162b2; SARS-CoV-2 mRNA EN COVID 19 vaccine CAR-T cells BNT162b2 SARS-CoV-2 mRNA 360 362 3 01/17/22 20220115 NES 220115 The efficacy of anti-SARS-CoV-2 messenger RNA vaccines was first demonstrated in healthy populations.1 It was later progressively reported in immunocompromised hosts, including patients with solid tumours,2 haematological malignancies, especially B-cell chronic lymphocytic leukaemia,3,4 as well as solid organ transplants.5,6 Surprisingly, the antibody response has been shown to be impressive (around 80%) only in recipients of allogeneic haematopoietic stem cells transplant.7-9 Another immunocompromised population is patients who have received chimeric antigen receptor-T (CAR T) cell therapy. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy. [Extracted from the article]